> TAP Pharmaceutical of Lake Forest, Illinois, has begun a late stage trial of TAK-390MR for the treatment of acid-related disorders. Release
> The FDA has approved Takeda Pharmaceutical's new combination drug for diabetes. The pharmaceutical, ActoPlus Met, combines Takeda's Actos and Metformin into a single tablet. Report
> Celera Diagnostics has identified four new genetic mutations that may play as big a role in heart attacks as smoking or high blood pressure. Story
> Pharmacopeia and Organon have extended their research collaboration. Release
> Manhattan Pharmaceuticals has raised $11.9 million in a private placement. Release
> Advaxis said its Listeria cancer vaccine has demonstrated a strong safety profile. Release
> Par Pharmaceutical has received final regulatory approval for a generic version of Bristol-Myers Squibb's Questran. Release
> Even if Biogen Idec and Elan find a way to put Tysabri back on the market for MS, one Wall Street analyst predicts that annual sales will only amount to a fraction of earlier forecasts. Story
And Finally… A group of dissident scientists at the National Institutes of Health are growing increasingly loud in their complaints focused on director Dr. Elias Zerhouni. Article